Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 plus apatinib or FOLFOX4 in advanced liver cancer
CTR20170196Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in hepatocellular carcinoma (HCC), extrahepatic cholangiocarcinoma (eCCA), gallbladder cancer, Common Bile Duct Cancer, sponsored by Hengrui Therapeutics. Started Mar 2017; status: completed.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)extrahepatic cholangiocarcinoma (eCCA)gallbladder cancerCommon Bile Duct Cancer
Beyond the preview
Go deeper on CTR20170196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170196.